7,580.07

-140.32

-1.82%

51,770.31

-572.29

-1.09%

25,437.00

-747.70

-2.86%

2,811.84

-47.38

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,809.98

+286.05

+0.37%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqGS - Delayed Quote USD

Boundless Bio, Inc. (BOLD)

2.4700 -0.0100 (-0.40%)

At close: October 30 at 4:00:00 PM EDT

Loading Chart for BOLD

Chart Range Bar

Interval:

In partnership with ChartIQ

Why Did BOLD, BLZE, QNT Stocks Surge To 52-Week Highs Today

Why Did BOLD, BLZE, QNT Stocks Surge To 52-Week Highs Today

Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement

Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement

Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights

Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights

Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why

Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer

Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer

Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer

Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer

BOLD Stock Is Up 90% — Here's What's Behind The Biggest Rally In Company History

BOLD Stock Is Up 90% — Here's What's Behind The Biggest Rally In Company History

Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Mobilize your Website

View Site in Mobile | Classic

Share by: